SynthesisFrontiers in pharmacology2025
Efficacy and safety of Jintiange in the treatment of osteoporosis: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and Safety of Celecoxib Combined With Jintiange Capsules for the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Medical science monitor : international medical journal of experimental and clinical research · 2026Trial
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- PBX1 promotes osteoporosis by upregulating HMGB1 to suppress osteogenic differentiation of bone marrow mesenchymal stem cells.Stem cell research & therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of Jintiange in osteoporosis treatment via systematic review and meta-analysis, thereby presenting more supporting evidence. Methods: Up to 27 October 2024, PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang were searched for studies on the use of Jintiange/artificial tiger bone powder in osteoporosis treatment. Studies were selected based on predefined eligibility criteria. Outcome measures encompassed bone mineral density (BMD), pain scores, adverse event (AE), fracture incidence, serum calcium, and phosphorus concentrations, as well as bone resorption and formation markers. Results: This study included 18 studies involving 21 trials on 2,580 patients (1,303 in the Jintiange group and 1,277 in the control group). A pooled analysis demonstrated that, in comparison to the control group, the Jintenge group achieved significantly greater improvements in BMD at various anatomical sites, including the lumbar spine (SMD = 0.52), femoral neck (SMD = 0.31), greater trochanter (SMD = 0.59), and Ward's triangle (SMD = 0.94). In addition, the Jintenge group exhibited a greater reduction in Visual Analogue Scale (VAS) scores (SMD = -0.87). No significant differences were observed between the two groups in terms of AEs or incidence of fractures. The level of bone Gla protein (BGP) was significantly higher in the Jintenge group compared with the control group (SMD = 1.28), whereas there were insignificant intergroup differences in serum calcium and phosphorus concentrations or changes in the type I collagen carboxy-terminal peptide (CTX). Sensitivity analysis revealed inconsistent results of Procollagen type I N-terminal propeptide (PINP) and bone alkaline phosphatase (BALP). Conclusion: Jintiange possibly improves BMD and alleviates pain in osteoporosis patients, with a favorable safety profile. Prolonged treatment duration (exceeding 6 months) yields greater therapeutic benefit than shorter courses, and the combination of Jintiange with standard therapies demonstrates superior efficacy relative to Jintiange alone. However, in consideration of the limitations of the present study, further high-quality investigations are necessitated to strengthen the evidence base and to elucidate the long-term efficacy, safety, and impact of this agent on fracture incidence. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42025630527.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.